Clinical trial
Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
NCT01570868 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 30, 2012
- Completion date
- May 31, 2016
- Enrollment
- 51 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.